Logo image of LNSR

LENSAR INC (LNSR) Stock Fundamental Analysis

NASDAQ:LNSR - Nasdaq - US52634L1089 - Common Stock - Currency: USD

12.76  -0.16 (-1.24%)

Fundamental Rating

2

LNSR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. LNSR may be in some trouble as it scores bad on both profitability and health. LNSR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LNSR has reported negative net income.
In the past year LNSR has reported a negative cash flow from operations.
In the past 5 years LNSR always reported negative net income.
In the past 5 years LNSR always reported negative operating cash flow.
LNSR Yearly Net Income VS EBIT VS OCF VS FCFLNSR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -77.57%, LNSR is not doing good in the industry: 76.47% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -77.57%
ROE N/A
ROIC N/A
ROA(3y)-34.59%
ROA(5y)-31.65%
ROE(3y)-81.1%
ROE(5y)-61.69%
ROIC(3y)N/A
ROIC(5y)N/A
LNSR Yearly ROA, ROE, ROICLNSR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1.3 Margins

LNSR has a Gross Margin of 47.86%. This is comparable to the rest of the industry: LNSR outperforms 42.25% of its industry peers.
LNSR's Gross Margin has improved in the last couple of years.
LNSR does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.25%
GM growth 5Y2.2%
LNSR Yearly Profit, Operating, Gross MarginsLNSR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

1

2. Health

2.1 Basic Checks

LNSR does not have a ROIC to compare to the WACC, probably because it is not profitable.
LNSR has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LNSR has been increased compared to 5 years ago.
LNSR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
LNSR Yearly Shares OutstandingLNSR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
LNSR Yearly Total Debt VS Total AssetsLNSR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -1.45, we must say that LNSR is in the distress zone and has some risk of bankruptcy.
LNSR has a worse Altman-Z score (-1.45) than 62.57% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -1.45
ROIC/WACCN/A
WACC8.91%
LNSR Yearly LT Debt VS Equity VS FCFLNSR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

LNSR has a Current Ratio of 1.81. This is a normal value and indicates that LNSR is financially healthy and should not expect problems in meeting its short term obligations.
LNSR has a worse Current ratio (1.81) than 69.52% of its industry peers.
A Quick Ratio of 1.25 indicates that LNSR should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.25, LNSR is doing worse than 68.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.81
Quick Ratio 1.25
LNSR Yearly Current Assets VS Current LiabilitesLNSR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

LNSR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -169.87%.
Looking at the last year, LNSR shows a very strong growth in Revenue. The Revenue has grown by 26.87%.
The Revenue has been growing by 11.87% on average over the past years. This is quite good.
EPS 1Y (TTM)-169.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.01%
Revenue 1Y (TTM)26.87%
Revenue growth 3Y15.79%
Revenue growth 5Y11.87%
Sales Q2Q%10.28%

3.2 Future

The Earnings Per Share is expected to grow by 29.52% on average over the next years. This is a very strong growth
Based on estimates for the next years, LNSR will show a very strong growth in Revenue. The Revenue will grow by 32.11% on average per year.
EPS Next Y85.38%
EPS Next 2Y39.89%
EPS Next 3Y29.52%
EPS Next 5YN/A
Revenue Next Year31.82%
Revenue Next 2Y30.58%
Revenue Next 3Y32.11%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LNSR Yearly Revenue VS EstimatesLNSR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
LNSR Yearly EPS VS EstimatesLNSR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LNSR. In the last year negative earnings were reported.
Also next year LNSR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LNSR Price Earnings VS Forward Price EarningsLNSR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LNSR Per share dataLNSR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as LNSR's earnings are expected to grow with 29.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.89%
EPS Next 3Y29.52%

More info and screens

0

5. Dividend

5.1 Amount

LNSR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LENSAR INC

NASDAQ:LNSR (8/13/2025, 3:31:04 PM)

12.76

-0.16 (-1.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners44.76%
Inst Owner Change6.63%
Ins Owners19.94%
Ins Owner Change8.64%
Market Cap150.44M
Analysts45.71
Price Target15.3 (19.91%)
Short Float %5.34%
Short Ratio4.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-1072.17%
Min EPS beat(2)-1367.43%
Max EPS beat(2)-776.91%
EPS beat(4)1
Avg EPS beat(4)-562.52%
Min EPS beat(4)-1367.43%
Max EPS beat(4)56.8%
EPS beat(8)3
Avg EPS beat(8)-295.58%
EPS beat(12)6
Avg EPS beat(12)-196.41%
EPS beat(16)9
Avg EPS beat(16)-144.39%
Revenue beat(2)2
Avg Revenue beat(2)6.84%
Min Revenue beat(2)3.59%
Max Revenue beat(2)10.09%
Revenue beat(4)4
Avg Revenue beat(4)7.77%
Min Revenue beat(4)1.96%
Max Revenue beat(4)15.42%
Revenue beat(8)5
Avg Revenue beat(8)5.03%
Revenue beat(12)6
Avg Revenue beat(12)0.94%
Revenue beat(16)10
Avg Revenue beat(16)3.57%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.64
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.21
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS4.84
BVpS-0.71
TBVpS-1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -77.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.86%
FCFM N/A
ROA(3y)-34.59%
ROA(5y)-31.65%
ROE(3y)-81.1%
ROE(5y)-61.69%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.25%
GM growth 5Y2.2%
F-Score3
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.48%
Cap/Sales 0.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.81
Quick Ratio 1.25
Altman-Z -1.45
F-Score3
WACC8.91%
ROIC/WACCN/A
Cap/Depr(3y)4.73%
Cap/Depr(5y)8.26%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-169.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%81.01%
EPS Next Y85.38%
EPS Next 2Y39.89%
EPS Next 3Y29.52%
EPS Next 5YN/A
Revenue 1Y (TTM)26.87%
Revenue growth 3Y15.79%
Revenue growth 5Y11.87%
Sales Q2Q%10.28%
Revenue Next Year31.82%
Revenue Next 2Y30.58%
Revenue Next 3Y32.11%
Revenue Next 5YN/A
EBIT growth 1Y7.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.65%
EBIT Next 3Y40.8%
EBIT Next 5YN/A
FCF growth 1Y78.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.39%
OCF growth 3YN/A
OCF growth 5YN/A